Isofol Medical AB (publ) represents values of innovation, scientific expertise, and patient-centered care. As a pharmaceutical company, Isofol Medical focuses on developing and commercializing innovative therapies for patients with unmet medical needs in oncology. The company's corporate philosophy revolves around harnessing the potential of its proprietary drug candidate, arfolitixorin, to improve the outcomes and quality of life for cancer patients. Isofol Medical is committed to conducting rigorous scientific research, collaborating with healthcare professionals, and prioritizing patient well-being. Through its dedication to innovation and patient-centric approach, Isofol Medical aims to make a meaningful difference in the field of oncology treatment.

Isofol Medical AB (publ) is primarily present in the countries and regions of Sweden, the United States, and Europe.

Isofol Medical AB (publ) has achieved several significant milestones. The company successfully completed a Phase 2 clinical trial for their lead product candidate, arfolitixorin, in metastatic colorectal cancer patients. They have also received Fast Track designation from the U.S. Food and Drug Administration (FDA) for arfolitixorin, which highlights the potential of their drug to address unmet medical needs. Isofol Medical AB (publ) has secured partnerships with prominent organizations, including Merck KGaA, enabling them to expand their reach and enhance the development of arfolitixorin. These milestones are indicative of the company's commitment to advancing innovative therapies for cancer treatment.

Isofol Medical AB (publ) is a Swedish pharmaceutical company specializing in the development of innovative treatments for patients with advanced colorectal cancer. Established in 2008, Isofol Medical AB has made significant advancements in the field of folate-based therapies. The company's lead product candidate, arfolitixorin, is an investigational drug being evaluated for its potential to enhance the efficacy of standard chemotherapy. Isofol Medical AB has a dedicated team of researchers and professionals working towards improving the outcomes and quality of life for cancer patients. With its commitment to advancing medical science, Isofol Medical AB (publ) aims to become a key player in the oncology pharmaceutical industry.

The main competitors of Isofol Medical AB (publ) in the market include companies such as F. Hoffmann-La Roche Ltd, Novartis AG, Puma Biotechnology Inc., AstraZeneca PLC, and Merck & Co., Inc.

Isofol Medical AB (publ) primarily operates in the pharmaceutical industry.

Isofol Medical AB (publ) operates as a clinical-stage biotech company. The company focuses primarily on developing and commercializing novel therapeutics for the treatment of cancer. Isofol Medical AB (publ)'s business model revolves around the development of its lead compound, arfolitixorin, which is being studied as a potential treatment for colorectal cancer. The company aims to address the unmet medical needs of patients by advancing its innovative drug candidates through various stages of clinical trials. Through strategic partnerships and collaborations, Isofol Medical AB (publ) aims to bring its novel therapies to market and ultimately improve patient outcomes in the field of oncology.

Isofol Medical AB (publ) KGV ir -49,51.

Isofol Medical AB (publ) KUV ir 6,28.

AlleAktien kvalitātes vērtējums Isofol Medical AB (publ) ir 4/10.

gaidāmā Isofol Medical AB (publ) apgrozījums ir 70,70 milj. SEK.

gaidāmā Isofol Medical AB (publ) peļņa ir -8,97 milj. SEK.

Isofol Medical AB is a biopharmaceutical company specializing in the development of products for cancer treatment. The company is working on the development of innovative therapies for various types of cancer, including those for which there are currently no effective treatments. Its current focus is on the development of a drug called "Modufolin" for the treatment of colorectal cancer, which is expected to be a promising alternative to the current standard therapy. Isofol Medical is also working on the development of another promising cancer drug called Neuostatin-1, which inhibits blood vessel growth and can thus slow down tumor cell growth. The company's business model revolves around collaboration with partners in the industry, science, and research, as well as distribution of its products. It already has distribution partnerships in Europe and the US and aims to expand its product portfolio in other regions of the world. Overall, Isofol Medical aims to develop and bring to market innovative cancer drugs that meet the needs of patients and physicians. It has a strong expertise in biomedical research and collaborates closely with partners in the industry and science to optimize and market its products. Through its focus on innovation and collaboration, Isofol Medical has the potential to become a leading company in cancer research and treatment.

Isofol Medical AB (publ) izmaksā dividendes 0 SEK, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Isofol Medical AB (publ) vai uzņēmums nedod dividendes.

Isofol Medical AB (publ) ISIN ir SE0009581051.

Isofol Medical AB (publ) WKN ir A2DPV6.

Isofol Medical AB (publ) simbols ir ISOFOL.ST.

Pēdējo 12 mēnešu laikā Isofol Medical AB (publ) maksāja dividendes 0,76 SEK apmērā. Tas atbilst aptuveni 27,47 % dividendes ražībai. Nākamajos 12 mēnešos Isofol Medical AB (publ) plāno maksāt dividendes 0,76 SEK apmērā.

Isofol Medical AB (publ) pašreizējā dividendu rentabilitāte ir 27,47 %.

Isofol Medical AB (publ) maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Isofol Medical AB (publ) pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0,76 SEK. Tas atbilst dividendes ražībai 27,47 %.

Isofol Medical AB (publ) tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Isofol Medical AB (publ) apmērā 0,755 SEK, kas tika izmaksāta 20.02.2023., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 14.02.2023..

Pēdējās dividendes izmaksa notika 20.02.2023..

Gadā 2023, Isofol Medical AB (publ) izmaksāja 0 SEK dividendes.

Isofol Medical AB (publ) dividendes tiek izmaksātas SEK.